Intensity-modulated radiation therapy for anal cancer.
The contemporary treatment of anal cancer is combined-modality therapy with radiation therapy, fluorouracil, and mitomycin. This therapy results in long-term disease-free survival and sphincter preservation in the majority of patients. Tempering these positive results is the high rate of treatment-related morbidity associated with chemoradiation therapy for anal cancer. The use of intensity-modulated radiation therapy (IMRT) has the potential to reduce acute and chronic treatment-related toxicity, minimize treatment breaks, and potentially improve disease-related outcomes by permitting radiation dose escalation in selected cases.
Czito
Brian G
BG
Department of Radiation Oncology, Duke University, School of Medicine, Durham, North Carolina, USA. czito001@mc.duke.edu
Pepek
Joseph M
JM
Meyer
Jeffrey J
JJ
Yoo
Sua
S
Willett
Christopher G
CG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D050397:Radiotherapy, Intensity-Modulated; D016032:Randomized Controlled Trials as Topic
D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil